Our Portfolio
From sepsis detection to sustainable agriculture, our portfolio companies are not making incremental improvements. They are building what comes next.
The Filter
Industry conviction. Business defensibility. Management excellence. We do not diversify for the sake of it. We concentrate on the sectors we know and the teams we believe in. These are those companies.
The Portfolio
These are the teams we chose — and the standard every new partnership has to meet.
Healthcare Diagnostics
Vail Scientific is revolutionizing sepsis detection with the VSNO™ breath analyzer, offering rapid, non-invasive diagnosis designed to become the new standard of care in emergency medicine.
“Their innovative approach to rapid sepsis screening is set to be the new standard of care. This investment will significantly enhance patient care.”
Agriculture · Plant-Based Food
CLO-CLO Foods is transforming how people think about nutritious, sustainable eating with delicious plant-based ingredients. A fast-growing wellness and lifestyle food brand with a founder-driven mission and expanding national distribution.
“One of Exit 156’s first two investments. A company built around the belief that eating well should not require compromise.”
Healthcare Technology · Staffing
Humla Health gives nurses and healthcare facilities direct access to one another to fill shifts, without the bloated cost of traditional staffing agencies. A fully digital, app-based platform built for the way healthcare labor actually works.
Exit 156 invested $2.0 million to complete Humla’s Series A round, accelerating market expansion and platform development.
“Humla Health is redefining what is possible in healthcare staffing. Their platform removes unnecessary friction and inefficiencies that have long plagued the industry. We believe Humla is building the future of healthcare labor.”
“This partnership with Exit 156 is a big milestone for Humla. With their backing, we can accelerate our roadmap and grow our team.”
Healthcare Services · Aesthetics
Blue Wolf Transformations offers precision body sculpting through innovative awake liposuction, delivering natural, permanent fat reduction with a patient experience built around safety, comfort, and results.
Healthcare Technology · AI
UrgentIQ streamlines urgent care workflows with AI-powered patient engagement and real-time communication tools. Faster throughput. Better patient experience. A platform built for the operational realities of modern urgent care.
Digital Health · FDA-Cleared
NightWare is the maker of the only FDA-cleared prescription digital therapeutic indicated for nightmare disorder in adults with PTSD. An AI-guided wearable system that intervenes during the nightmare cycle without waking the patient. Currently executing a national VA Pathfinder Innovation Pilot with active expansion into first responder markets.
“When we looked at the full picture, the clinical evidence, the reimbursement in place, the VA pilot, and a team that knows how to execute, the decision to invest at the Series C level was clear.”
“Exit 156 doesn’t invest in categories. They invest in people and proof. We have both.”
De Novo 510(k) FDA Cleared · Breakthrough Device Designation · VA Pathfinder Innovation Pilot · Series C
What’s Next
We are currently raising capital and evaluating opportunities in healthcare services, devices, and technology. If you are a founder with a company that fits our thesis, or a deal source with an opportunity worth exploring, we want to hear from you.
Whether you are a founder, a deal source, or an investor exploring the fund, our process starts with a direct conversation.
